-
Primary percutaneous coronary intervention (PCI) saves lives in patients suffering from ST-elevation myocardial infarction (STEMI).
-
Side effects of finasteride; new ruling on pharmaceutical companies paying generic manufacturers; and FDA actions.
-
This paper discusses the clinical utility of impulse and rotor mapping to guide atrial fibrillation (AF) ablation and is a follow-up to the acute observations discussed in Clinical Cardiology Alert several months ago.1 The authors hypothesized that AF is sustained by localized sources that may be targeted during AF ablation procedures.
-
New treatment for prostate cancer; avastin and breast cancer; new CMS disclosure rule; and FDA actions.
-
Peripheral arterial disease (PAD) can cause symptomatic claudication and it can reduce quality of life.
-
The management of asymptomatic patients with severe aortic stenosis (AS) is controversial. Patients meeting standard echocardiographic criteria for severe stenosis have a variety of pressure gradients and flow rates that can be divided into four categories based on normal flow vs low flow (NF vs LF) and low gradient vs high gradient (LG vs HG), where LF is defined as a stroke volume index (SVI) of < 35 mL/m2 and LG is a mean gradient < 40 mmHg.
-
After acute coronary syndromes (ACS), patients remain at risk for recurrent cardiovascular events. Antiplatelet agents are the mainstay of secondary preventive strategies aimed at reducing the rate of recurrent events.
-
The Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT) tested two hypotheses.
-
Although electrocardiogram (ECG) left ventricular hypertrophy (LVH), especially with ST-T changes (strain pattern), is known to be of prognostic value in patients with aortic stenosis, its valve in patients who are being followed is unclear.
-
